| Literature DB >> 33124429 |
William Mahy1, Nicky J Willis1, Yuguang Zhao2, Hannah L Woodward1, Fredrik Svensson1,3, James Sipthorp1,3, Luca Vecchia2, Reinis R Ruza2, James Hillier2, Svend Kjær3, Sarah Frew1, Amy Monaghan1, Magda Bictash1, Patricia C Salinas4, Paul Whiting1, Jean-Paul Vincent3, E Yvonne Jones2, Paul V Fish1,3.
Abstract
Carboxylesterase Notum is a negative regulator of the Wnt signaling pathway. There is an emerging understanding of the role Notum plays in disease, supporting the need to discover new small-molecule inhibitors. A crystallographic X-ray fragment screen was performed, which identified fragment hit 1,2,3-triazole 7 as an attractive starting point for a structure-based drug design hit-to-lead program. Optimization of 7 identified oxadiazol-2-one 23dd as a preferred example with properties consistent with drug-like chemical space. Screening 23dd in a cell-based TCF/LEF reporter gene assay restored the activation of Wnt signaling in the presence of Notum. Mouse pharmacokinetic studies with oral administration of 23dd demonstrated good plasma exposure and partial blood-brain barrier penetration. Significant progress was made in developing fragment hit 7 into lead 23dd (>600-fold increase in activity), making it suitable as a new chemical tool for exploring the role of Notum-mediated regulation of Wnt signaling.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33124429 DOI: 10.1021/acs.jmedchem.0c01391
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446